4D Molecular Therapeutics (FDMT) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$1.05
- Surprise
- —
- Score today
- 5.1/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- 4D Molecular Therapeutics Named to BioSpace 2027 Best Places to Work List — fiscal.ai, 2026-11-10
Where TrendMatrix's rating stands now
TrendMatrix currently rates FDMT Sell at 5.1/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate.
What argues against it
- Quality below floor (2.5 < 4.0)
- Insider activity: 0.38%=heavy
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.99
- Price target
- $24.44
- Stop
- $12.08
- Upside to target
- +88.1%
- Reward-to-risk
- 5.9:1
Model outputs from TrendMatrix’s engine as of 2026-11-12 — shown for context, not personalized investment advice.
FDMT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $717.6M
- P/E (fwd)
- -3.2
- 52-week range
- $6.96–$16.93
- Off 52-week high
- 23.3%
- RSI (14)
- 57
- Volume vs avg
- 0.83×
- Score today
- 5.1/10